Vivos Therapeutics, Inc. Q3 2025 Earnings Recap

Vivos experienced a landmark third quarter 2025, reporting a 76% year-over-year revenue increase to $6.8 million, driven by the successful integration of the Sleep Center of Nevada.

Key Takeaways

• Revenue from OSA sleep testing services surged by $2.2 million, primarily from the newly acquired SCN and two treatment centers in Las Vegas.
• The company's gross profit increased to $3.9 million, with a gross margin of 58%, despite rising costs linked to SCN integration.
• VIP enrollment revenue from the legacy model decreased by $800,000, confirming a strategic pivot toward a more sustainable revenue stream through service and product offerings.
• Year-to-date revenue increased by 20% to $13.6 million, highlighting strong momentum following the acquisition.
• General and administrative expenses rose 42% to $19.2 million, primarily due to increased costs from SCN operations.